Racial Differences in Responses to Drug Treatment
Authors:
- 1 January 2002
- journal article
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 2 (6) , 389-399
Abstract
Chronic heart failure (CHF) is a common disease with high associated morbidity and mortality, and the outcome appears to be worse in black compared with white patients. There is currently no clear consensus for basing the pharmacological treatment of CHF on racial differences. Most studies that have investigated the potential effects of racial differences on pharmacological responses in heart failure have been based on African Americans and white participants. Using these data, this review will discuss the current understanding of the effects of racial differences in response to pharmacotherapy in heart failure, possible mechanisms for these observed differences, and how this may impact on patient management.Keywords
This publication has 6 references indexed in Scilit:
- Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive NephrosclerosisA Randomized Controlled TrialJAMA, 2001
- The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trialCurrent Controlled Trials in Cardiovascular Medicine, 2001
- Why is plasma renin activity lower in populations of African origin?Journal of Human Hypertension, 2000
- Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein:JACC, 1999
- ACE Inhibition and Heart FailureCirculation, 1998
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987